Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

HIV Medicine

Volumn 16, Issue 9, 2015, Pages 544-552

  Mansfeld, M ^a   Skrahina, A ^b   Shepherd, L ^c   Schultze, A ^c   Panteleev, Am ^d,e   Miller, Rf ^f   Miro, Jm ^g   Zeltina, I ^h,p   Tetradov, S ^i,j,p   Furrer, H ^k,p   Kirk, O ^a,p   Grzeszczuk, A ^l,p   Bolokadze, N ^m,p   Matteelli, A ^n,p   Post, Fa ^o   Lundgren, Jd ^a   Mocroft, A ^c   Efsen, Amw ^a   Podlekareva, Dn ^a   Losso, M H ^p   Toibaro, J J ^p   Palmero, D ^p   Bartoletti, B J ^p   E Warley, ^p   Gear, O ^p   Messina, O G ^p   Michans, M ^p   Laplume, H ^p   David, D ^p   Marson, C ^p   Scapelatto, F P ^p   Dalessandro, D ^p   Lupo, S ^p   Costilla Campero, G ^p   Herbst, M ^p   Remondegui, C ^p   Elias, C ^p   Karpov, I ^p   Vassilenko, A ^p   Skrahina, E ^p   Skrahin, A ^p   Zalutskya, A ^p   Kondratenko, O ^p   Mitsura, V ^p   Bondarenko, V ^p   Suetnov, O ^p   Paduto, D ^p   Dewit, S ^p   Payen, M C ^p   Noscoi, C ^p   Kabeya, K ^p   M Wolff, ^p   Cortes, C ^p   Obel, N ^p   Kronborg, G ^p   Iljna, V ^p   Kummik, T ^p   Bryand, M ^p   Dabis, F ^p   Lanchava, N ^p   Bablishvili, N ^p   Goginashvili, L ^p   Mikiashvili, L ^p   Mshvidobadze, K ^p   Girardi, E ^p   Di Biagio, A ^p   Apostoli, A ^p   Barzoni, S ^p   Lapadula, G ^p   Purgatorio, M ^p   Carbonara, S ^p   Rozentale, B ^p   Janushkevich, I ^p   Caplinskas, S ^p   Kancauskienne, Z ^p   Caplinskienne, I ^p   Crabtree, B ^p   Pina, A ^p   Madero, J S ^p   Mosqueda, J ^p   Villanueva, J A ^p   Bura, M ^p   Garlicki, A ^p   Inglot, M ^p   Knysz, B ^p   Kozlowska, J ^p   Loster, J ^p   Mularska, E ^p   Podlasin, R ^p   Thompson, M ^p   Wiercinska Drapalo, A ^p   Duiculescu, D ^p   Rakhmanova, A ^p   Yakovlev, A ^p   Panteleev, A ^p   Turkalova, A ^p   Vlasova, Y ^p   Trotimora, T ^p   Borodulina, E ^p   Chumanova, L ^p   Mashkova, Y ^p   Miro, J M ^p   Cayla J A ^p   Moreno, A ^p   Millet, J P ^p   Orcau, A ^p   Fina, L ^p   del Bano L ^p   Roldan L L ^p   Romero, A ^p   Martinez J A ^p   Manzardo, C ^p   Gonzalez J ^p   Tudo, G ^p   Knobel, H ^p   Sanchez, F ^p   Salvado M ^p   Curran, A ^p   Tortola M T ^p   Pozamczer, D ^p   Saumoy, M ^p   Alcaide, F ^p   Martinez Lacasa X ^p   Cuchi E ^p   Sambeat, M A ^p   Pomar, V ^p   Coll, P ^p   Miralles, P ^p   Moreno, S ^p   Iribarren, J A ^p   Ibarguren, M ^p   Aldamiz, T ^p   Rickenbach, M ^p   Sagette, M ^p   Post, F A ^p   Miller, R F ^p   Chapman, A ^p   Dockrell, D ^p   Wilkins, E ^p   Cooke, G ^p   Ainsworth, J ^p   Macallen, D ^p   Dhar, J ^p   Vora, N ^p   Mullaney, S ^p   Kegg, S ^p   Kyselyova, G ^p   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Institute of Pulmonology and Tuberculosis   (Belarus)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d City Oncology Hospital   (Russian Federation)

^e St Petersburg Munic Geriatric Ctr   (Russian Federation)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF BARCELONA   (Spain)

^h Infectology Centre of Latvia   (Latvia)

ⁱ VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^j CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^k UNIVERSITY OF BERN   (Switzerland)

^l MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^m Infectious Diseases AIDS and Clinical Immunology Research Center   (Georgia)

ⁿ UNIVERSITY OF BRESCIA   (Italy)

^o KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^p NONE   (Ukraine)

more..

Author keywords

Delivery of health care; Europe; HIV; Integrated; Tuberculosis

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMIKACIN; AMINOSALICYLIC ACID; ARGININE; BEDAQUILINE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LAMIVUDINE PLUS ZIDOVUDINE; LEVOFLOXACIN; LINEZOLID; NARCOTIC ANALGESIC AGENT; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; THIOACETAZONE; THIORIDAZINE; VIOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; BELARUS; CLINICAL PRACTICE; DENMARK; EASTERN EUROPE; ESTONIA; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LATVIA; MIXED INFECTION; MULTICENTER STUDY; OPIATE SUBSTITUTION TREATMENT; POLAND; PRIORITY JOURNAL; ROMANIA; RUSSIAN FEDERATION; SCREENING TEST; SHORT COURSE THERAPY; SPAIN; SWITZERLAND; TUBERCULOSIS; UKRAINE; UNITED KINGDOM; WESTERN EUROPE; CLINICAL TRIAL; COINFECTION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; EUROPE; HIV INFECTIONS; MICROBIOLOGY; PROCEDURES;

ANTITUBERCULAR AGENTS; COINFECTION; CROSS-SECTIONAL STUDIES; EUROPE; EUROPE, EASTERN; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; OPIATE SUBSTITUTION TREATMENT; RIFABUTIN; TUBERCULOSIS;

EID: 84940790647     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12256     Document Type: Article

References (26)

1. UNAIDS. UNAIDS Report on the Global AIDS Epidemic. Geneva, UNAIDS, 2013. Available at http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (accessed 02 December 2013).
2. WorldHealth Organization. Global Tuberculosis Report. Geneva, World Health Organization., 2014. Available at http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf?ua=1 (accessed 02 December 2014).
3. Podlekareva DN, Mocroft A, Post FA etal. HIV/TB Study Writing Group. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS 2009; 18: 2485-2495.
4. Dehovitz J, Uuskula A, El-Bassel N. The HIV epidemic in Eastern Europe and Central Asia. Curr HIV/AIDS Rep 2014; 11: 168-176.
5. Dara M, Dadu A, Kremer K, Zaleskis R, Kluge HH. Epidemiology of tuberculosis in WHO European Region and public health response. Eur Spine J 2013; 4: 549-555.
6. Dooley KE, Kim PS, Williams SD, Hafner R. TB and HIV therapeutics: pharzmacology research priorities. AIDS Res Treat 2012; 2012: 874083. [Epub 2012 Jul 5].
7. Skrahina A, Hurevich H, Zalutskaya A etal. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 2013; 91: 36-45.
8. World Health Organization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, World Health Organization, 2010. Available at http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf (accessed 12 January 2014).
9. WorldHealth Organization. The global plan to stop tuberculosis 2006-2015. Stop TB partnership. Geneva, World Health Organization, 2006. Available at http://www.stoptb.org/assets/documents/global/plan/GlobalPlanFinal.pdf (accessed 12 January 2014).
10. Floyd K, Hutubessy R, Samyshkin Y etal. Health-systems efficiency in the Russian Federation: tuberculosis control. Bull World Health Organ 2006; 84: 43-51.
11. Dimitrova B, Balabanova D, Atun R, Drobniewski F, Levicheva V, Coker R. Health service providers' perceptions of barriers to tuberculosis care in Russia. Health Policy Plan 2006; 21: 265-274.
12. Lazarus JV, Olsen M, Ditiu L, Matic S. Tuberculosis-HIV co-infection: policy and epidemiology in 25 countries in the WHO European region. HIV Med 2008; 9: 406-414.
13. Podlekareva DN, Grint D, Post FA etal. for the HIV-TB Study Group. Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. Int J Tuberc Lung Dis 2013; 17: 198-206.
14. Keshavjee S, Gelmanova IY, Pasechnikov AD etal. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008; 1136: 1-11.
15. Perelman MI. Tuberculosis in Russia. Int J Tuberc Lung Dis 2000; 4: 1097-1103.
16. WorldHealth Organization. WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholders. Geneva: World Health Organization, 2012. Available at http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf (accessed 12 January 2014).
17. Kerschberger B1, Hilderbrand K, Boulle AM etal. The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study. PLoS ONE 2012; 7(10): e46988.
18. Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy 2007; 18: 306-312.
19. Havlir DV, Kendall MA, Ive P etal. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. NEJM 2011; 365: 1482-1491.
20. Blanc F, Sok T, Laureillard D etal. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. NEJM 2011; 365: 1471-1481.
21. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007; 18: 262-270.
22. Grenfell P, Baptista Leite R, Garfein R, de Lussigny S, Platt L, Rhodes T. Tuberculosis, injecting drug use and integrated HIV-TB care: a review of the literature. Drug Alcohol Depend 2013; 129: 180-209.
23. Marco A, Caylà JA, Serra M etal. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998; 12: 967-971.
24. Lazarus JV, Hoekstra M, Raben D, Delpech V, Coenen T, Lundgren JD. HIV in Europe Initiative Steering Committee. The case for indicator condition-guided HIV screening. HIV Med 2013; 14: 445-448.
25. Lessem E, Keshavjee S. Russia: drug-resistant TB can be contained. Nature 2014; 506: 295.
26. Lönnroth K, Castro KG, Chakaya JM. Tuberculosis control and elimination in 2010-50: cure, care, and social development. Lancet 2010; 375: 1814-1829.